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Abstract
BACKGROUND: Ulcerative colitis (UC) is a relapsing chronic inflammatory disorder, with many catastrophic 
complications. The pathogenesis of UC is not yet well understood. Exploring the exact immunologic pathogenesis of 
UC may eventually offer new therapeutic options.
AIM OF THE WORK: In this study, we proposed that survivin and programmed death ligand (PDL1) may have roles 
in the pathogenesis of UC.
MATERIALS AND METHODS: The study examined the immunohistochemical expression of both markers in the 
colonic epithelial cells and lamina propria in 43 cases of UC and 43 cases of non-specific chronic colitis (non-
inflammatory bowel disease colitis).
RESULTS: The results uncovered that both survivin and PDL1 expression were significantly expressed in the colonic 
lamina propria cells in UC cases in comparison to colitis cases (p < 0.001). On the other hand, the expression of 
PDL1 was shown to be lost in the colonic mucosal cells in UC cases when compared to cases of the control group 
(p < 0.05).
CONCLUSION: The study, therefore, concluded that both survivin and PDL1 may play an important role in the UC 
pathogenesis and hence may be a novel interest in new therapeutic trends.
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Introduction
Ulcerative colitis (UC) is a chronic relapsing 
inflammatory bowel disease (IBD) that diffusely involves 
various parts of the colon, without skip lesions [1]. 
UC is usually presented by bloody diarrhea, rectal 
tenesmus, and abdominal pain. Colonoscopic examination 
is the fundamental diagnostic tool, as well, it assesses the 
disease activity, which guides the management strategy, 
and is the basic method for patient follow-up [1]. 
During disease activity, the affected areas of 
colonic mucosa show ulcers, exudates, fragile mucosa, 
and bleeding. The symptoms are greatly controlled 
by drugs which induces remissions. However, all the 
symptoms and signs of activity will eventually recur 
easily in the following exacerbation attacks [2]. 
The etiopathogenesis of UC is not yet clear and 
not until now fully understood; genetic and epigenetic 
factors are supposed to play a role [3]. Abnormal altered 
response of the mucosal immune cells to normally 
existent gut flora in genetically susceptible individuals 
is the most believed theory, the event that leads to 
increase many inflammatory chemical mediators, create 
a sustained state of oxidative stress, establish chronic 
inflammation, and disturb the colonic bacterial profile [4]. 
Many inflammatory cells are implicated in such 
process, with most of the studies strongly suggest a 
prominent role of T helper lymphocyte family including; 
CD 4+ helper cells types 1 and 2 (Th1 and Th2), 
CD4+ cells which produce interleukin-17 (Th17), and 
regulatory T cells (Treg) [5]. 
It was shown that the abnormal immune 
response to the gut flora seen in UC is accompanied by 
prompt increase in mucosal T cells, mainly Th1 and Th2 
subsets, dysregulation of their responses, and faulty T cell 
inactivation that results in self- intolerance and autoimmune 
process development, however, to the moment, the 
mechanism underlying these events is not fully explored.
Survivin is a well-known apoptosis inhibitor, 
which modulate its antiapoptotic activity through 
direct inhibition of cytoplasmic caspase [6]. In the last 
years, survivin is proved to have a significant role in 
carcinogenesis by crippling the process of apoptosis in 
the cancer cells, the step which enables the cancer cells 
to dart the body’s immune surveillance mechanisms [7]. 
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It is also proved that survivin promotes T-cell 
proliferation, and differentiation, and hence has a major 
directory role in the pathogenesis of many autoimmune 
disorders [8].
Whether survivin has such similar role in 
the pathogenesis of UC which is still an uncovered 
interesting issue for research. 
Programmed death 1 (PD-1) is a coinhibitory 
receptor known to be expressed on T cells, B cells, 
monocytes, and natural killer cells [9].
PD-1 is a member of the B7-CD28 family and 
has two ligands, PD ligand-1 and -2 (PD-L1 and -L2), 
both play different roles in the regulation of Th1-Th2 
cell function; PD-L1 is proposed to inhibit Th1 
responses, while, PD-L2 is suggested to modulate 
Th2 function [10]. 
The possible role of PD-1 ligands in UC is 
another novel area for exploration. 
In this study, we examined the 
immunohistochemical expression of survivin and PD-L1 
in UC cases of as step to explore their possible role in 
UC pathogenesis and progression. 
Materials and Methods
Cases and group
This study was retrospective study on archived 
paraffin blocks in the period from 2016 to 2019, from 
pathology departments in Air Force Specialized Hospital 
and Nasser Institute for Research and Treatment, Cairo, 
Egypt, according to the following inclusion criteria:
• Availability of required patient data regarding 
sex and age.
• Availability of the paraffin block with adequate 
tissue for sectioning. 
Cases with a history of prior treatment were 
excluded from the study.
The study was approved by the ethical committee 
of Zagazig University (ZU. IRB: 6147-31-1-2019). 
The study included 86 cases; 43cases 
diagnosed as UC and 43 cases of non-specific colitis. 
The hematoxylin and eosin stained slides were 
revised for confirmation of the diagnosis. 
Two slides were cut from each block at 3–5 
micron for immunohistochemical stains.
The immunohistochemical stains were 
performed as following
The immunohistochemical method was 
performed by an automated immunostainer (Ventana 
BenchMark XT; USA) which run the following 
basic steps: Section deparaffinization with xylene, 
rehydration with alcohol and then saturation with 
0.03% hydrogen peroxide. This was followed by 
antigen retrieval with Tris-buffered 0.1% saline-
Tween-20 at pH = 7.6. Incubation was done with 
the primary antibodies using anti-PD-L1 antibody 
(M3653 clone 22C3, Dako, Glostrup, Denmark) and 
survivin Ab 17 antibody (M3624, Clone 12C4. Dako, 
Carpinteria, CA, USA) at 1:400 dilution for 30 min at 
room temperature. 
The UltraView Universal DAB Detection Kit 
was used as the secondary antibody in the device.
Samples were finally counterstained with 
hematoxylin and mounted in DPX.
Evaluation of immunohistochemical 
staining
As monoclonal antibodies to PD-L1 are 
directed to the extracellular domain of its molecule, so, 
immunohistochemistry (IHC) staining stains epithelial 
and immune cells with a mixture of cytoplasmic and 
membrane staining [11]. 
The expression of PD-L1 staining in the 
epithelial cells is estimated and scored from 0 to 3 
according to the percentage of positive cells (0, 0%; 
1, <25%; 2, 25–50%; and 3, >50%). Staining intensity 
was assigned as weak if there was absent or barely 
identifiable staining at ×10 power, moderate if easily 
perceptible at ×10 power, and intense if easily seen 
at ×4 power. Only cases with moderate-to-intense 
staining intensity were considered positive. Lesions 
were considered as positive for PD-L1 expression in 
epithelium when they show at least moderate staining 
intensity in at least 25% of cells in at least 50% of 
HPs [12]. 
Evaluation of survivin expression was done 
semi-quantitatively by grading the intensity of staining 
(0, absent; 1, weak; 2, moderate; and 3, strong) 
and determining the percentage of positive cells. 
The H-score was then obtained by multiplying the 
percentages of the stained cells by the intensity score 
of staining. Therefore, the final score values ranged 
from 0 up to 300. According to Jakubowska et al., cases 
were reported as negative when H-score <150 and 
positive when H-score equals or more than 150 [13].
According to Wyss et al.., PD-L1 staining in the 
stroma (lamina propria) was evaluated subjectively and 
classified according to the percentage of positive cells 
within the total area of the lamina propria as: 0: negative, 
1: 0.1–1%, 2: > 1–5%, 3: >5–50%, and 4: >50%. PD-L1 
positivity in areas of ulceration was not evaluated [14]. 
Dot-like cytoplasmic staining as well as nuclear staining 
patterns for PD ligand (PDL)-1 were counted as negative 
[14]. The expression of survivin in the lamina propria was 
evaluated using the same scoring system used in PDL1. 
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For statistical purposes, the scores of lamina 
propria positive cells for both markers are subgrouped 
as low infiltration pattern (including scores 0, 1, 
and 2) and high infiltration pattern (including scores 
3 and 4). 
Statistical method
• Data entry was done using Microsoft Excel 
2013 and data analysis was mediated by the 
Statistical Package for the Social Sciences 
(SPSS version 24).
• Simple descriptive statistics (arithmetic mean 
and standard deviation [SD]) used for summary 
of normal quantitative data and frequencies 
used for qualitative data.
• Bivariate relationship was displayed in cross-
tabulations and comparison of proportions was 
performed using the Chi-square test.
• Independent t-test was used to compare 
normally distributed quantitative data.
• The level of significance was set at p < 0.05.
Results
The study included 86 cases; of them, 43 
cases of UC and 43 cases of non-specific (non-IBD) 
colitis as a comparative control group. 
Epidemiological findings
Gender distribution
(Figure 1) The study population were 50 males 
and 36 females. 
In the UC group cases, 30 were male (69.8%) 
and 13 were female (30.2%). The non-specific colitis 
cases included 20 males (46.5%) and 23 females 
(53.5%). The difference between the two groups is 
significant (p = 0.029). 
Age distribution
The overall age of the cases ranged from 18 
up to 67 years with mean 40.36 and median 39.00. 
Within the UC group, the age ranged from21 
years up to 65 years; with mean 41.23 ± SD 11.497.
In the non-specific colitis group, the age 
ranged from 18 years to 67 years, with mean 39.49 ± 
SD 11.895. 
The difference between the two groups was 
statistically insignificant (p = 0.491). 
Immunohistochemical results
Results are shown in Table 1 and Figure 1. 
Figure 1: Immunoexpression of both markers in the two diagnostic 
groups; a: Programmed death ligand (PDLI) expression in ulcerative 
colitis (UC) cases showed loss of membranous and cytoplasmic 
expression in the colonic gland cells. The lamina propria showed 
increased infiltration by the PDL1-positive cells (PDL1 ×200). 
b: PDL1 expression in a case of non-specific colitis showing constant 
expression in the colonic gland epithelial cells with few cells in the 
stroma positive to it (PDL1 ×200). C: Survivin expression in a case of 
UC showing expression in the cells of the colonic glands and marked 
lamina propria infiltration by survivin-positive cells (survivin ×200). 
D: Survivin expression in a case of non-specific colitis showing 
diffuse strong expression in the colonic gland cells with few positive 
cells in the lamina propria (survivin ×200)
dc
ba
Results of immunohistochemical expression 
of survivin
Survivin expression in the colonic epithelial 
cells was seen in total 70 of the studied cases (81.4%); 
33 cases of UC and 37 cases of non IBD colitis, with 
no statistical difference between the two groups (p = 
0.268). 
Regarding the lamina propria, the infiltration 
of survivin positive cells was high in all the cases of 
UC (100%) and low in all cases of non-specific colitis 
(p < 0.001). 
Results of immunohistochemical expression 
of PDL1
In the epithelial cells of colonic mucosa, PDL1 
was positive in 50 cases of the studied population. 
UC cases showed positive expression for 
PDL1 in 12 of them (27.9%) compared to 31 negative 
cases (72.1%). 
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Within non-IBD colitis cases, 38 cases were 
positive (88.4%) and 5 cases were negative (11.6%). 
The difference between the two studied groups was 
significant (p < 0.001).
Counting the PDL1-positive cells in the lamina 
propria in the studied cases showed high infiltration rate 
in 35% of the UC cases and 0% of non-specific colitis 
cases (p < 0.001). 
Table 1: Comparative results between the two study groups
Group p value
Ulcerative colitis cases Non-specific colitis cases
Count (5) Count
PDL1 epi
Negative 31 (72.1) 5 (11.6) *<0.001
Positive 12 (27.9) 38 (88.4)
PDL1 LP
Low infiltrate 8 (18.6) 43 (100) *<0.001
High infiltrate 35 (81.4) 0 (0)
Surv epi
Negative 10 (23.3) 6 (14) 0.268
Positive 33 (76.7) 37 (86)
Surv LP
Low infiltrate 0 (0) 43 (100) *<0.001
High infiltrate 43 (100) 0 (0)
PDL1 epi.: Expression of PDL1 in epithelial colonic cells, PDL1 LP: Infiltration of the lamina propria by PDL1 
positive cells, Surv epi: Expression of survivin in epithelial colonic cells, Surv LP: Infiltration of the lamina 
propria by survivin-positive cells. *: Statistical significance.
Discussion
UC is a chronic remitting relapsing disease 
that is characterized by diffuse mucosal epithelial 
damage and ulceration with ultimate persistent increase 
inflammatory cell infiltrate [1]. 
The pathogenesis of UC is not clear until 
now. The role of different inflammatory mediators and 
cells, their persistent activation triggers, and their 
interaction with the mucosa is still a dynamic area for 
research [5]. 
In this study, we proposed that survivin and 
PDL-1 may play a significant role in UC pathogenesis. 
The study included 43 retrospective cases of UC and 
43 cases of non-specific colitis from two centers. The 
expression of PDL1 and survivin both in the lamina 
propria and the colonic glands’ epithelial cells in both 
groups was examined using IHC technique. 
The studied cases showed a male-to-female 
ratio near to 7: 3 in the UC group and 1:1 in the non-specific 
colitis group, with statistically significant difference 
(p = 0.029). Although the number of the included cases 
in this study is not satisfactory to conclude such gender 
association, this result was somewhat in concordance to 
the results of Saha et al. who noticed a significant male 
higher incidence of UC. However, they restricted this to 
cases above the age of 45 years [15]. 
According to our results, survivin expression 
in the colonic glandular cells showed no statistical 
difference between the two groups (p = 0.268), while a 
significant upregulation of lamina propria positive cells 
between both groups was obtained (p < 0.001). 
The high density of survivin-positive cells in 
the lamina propria in UC cases may be then attributed 
to the its important role as an apoptosis inhibitor and 
may explain that the autoreactive T cells in UC patient 
do not undergo apoptosis and hence can sustain a 
state of continuous chronic inflammation seen in such 
disorder [16]. 
Some studies have examined the status of 
survivin in UC, Rapti et al. examined the levels of survivin 
expression in UC patients using real-time reverse 
transcriptase-polymerase chain reaction (PCR) on 
blood samples and fresh tissue biopsies in their case–
control study. They concluded that high level of survivin 
expression was associated with the accumulation of T 
cells and cessation of apoptosis in them [17]. 
In similar regards, Feng et al. have highlighted 
the possible role of survivin in accumulation of T 
cells in the lamina propria in UC patients through the 
interference of their apoptosis. In their study, they 
collected samples from peripheral blood of UC patients 
and healthy subjects and examined the apoptotic status 
in T cells using the flow cytometry technique [18]. 
The appealing features of survivin were 
comprehensively discussed by Pahlavan et al. who 
introduced survivin as a strong potential biomarker 
and important player in the pathogenesis of different 
autoimmune disorders and auto-inflammatory 
conditions, through its ability to hinder the apoptotic 
machine in many different pathways [19]. 
Regarding PDL1 expression, we agreed with 
other authors who pointed to that the IHC interpretation 
of this marker was hard and relatively complicated in 
many aspects, including the rarity of comparable studies 
discussing its expression in non-tumorous diseases, 
as well as the multiplicity of the antibody clones and 
the nature of the protein being a biological gradient 
from totally absent, to low, to intermediate, to high that 
lead to wide staining heterogenicity and interpretation 
difficulty [20, 21]. 
In our cases, evaluation of PDL1 expression 
showed a significant raise in the lamina propria positive 
cells between the UC cases versus the non-specific 
(non-IBD colitis) (p < 0.001). On the other hand, a 
strong significant loss of PDL1 expression was noticed 
in cases of UC group when compared with non-specific 
colitis cases (p < 0.001). 
The spiked increase of PDL1-positive cells 
in the lamina propria cases was documented in few 
previous studies, some of which had also studied the 
nature of these cells. 
Mezache et al. have appreciated the high 
density of PDL1-positive lamina propria cells in cases 
UC and suggested that the nature of these cells was 
mainly CD8 + T lymphocytes [9]. 
Brusa et al. pointed to the fact that PDL1 will 
be highly expressed in actively proliferating T and B 
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lymphocytes [22], the fact that may explain the high 
expression of it in the lamina propria of UC cases as a 
persistently immunologically activated media destroying 
the colonic glands epithelial layer [23]. 
In similar regards, Beswick et al. have 
concluded that PDL1 expression is upregulated in 
both the intestinal epithelial cells and many cells in 
the lamina propria. They detailed the nature of these 
positive cells to include B lymphocytes, macrophages, 
and myofibroblasts [24]. Nevertheless, they found that 
the proposed role of PDL1 is still under investigation 
and that the few published data in this regard are still 
contradictory [24]. 
Using the modality of quantitative real-time 
PCR, Rajabian et al. studied the proposed role 
of PDL1 in the pathogenesis of UC by measuring 
the level of gene expression in such cases. They 
suggested that PDL1 and 2 may act as an important 
regulator of the immune response in UC; however; 
they recommended further extensive studies for 
better understanding of their exact role and the 
possible benefits from these data in generating 
related therapeutic options [5].
Based on the fact that normal body cells 
express PD-L1 protein in order to avoid the damage by 
T cells, which detect body cells’ transmembrane PDL1 
by their surface PD1 receptors, leading to immune 
response downregulation and T cells apoptosis [21]. 
Thus, the possible explanation of altered PDL1 
expression in UC; in the way that prevent the PDL1/
PD1 interaction and therefore prevent the loop of T cell 
inactivation and their apoptosis, the step which may 
explain the accumulation of T cell in the lamina propria 
of UC cases and their persistent activation. In similar 
fashion, this will explain the accumulation of T cell in the 
lamina propria of UC cases. 
The loss of PDL1 expression in colonic glands 
mucosal cells in UC is also supported by the incidence 
of the newly recognized UC like colitis which was 
reported as a common side effect of PDL1 inhibitors 
drugs, possibly by similar mechanism of pathogenesis, 
however, clear understanding of this type of colitis is not 
yet provided [25, 26]. 
Conclusion
We pointed to that both PDL1 and survivin may 
have roles in the pathogenesis of UC, we, therefore, 
recommend further studies to explore their detailed 
mechanism of action and pathway effectors which may, 
in turn, suggest novel related treatment modalities 
for UC. 
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